Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort – The Tumor Anemia Registry.

Steinmetz, T., Schröder, J., Plath, M., Link, H., Vogt, M., Frank, M., Marschner, N., 2016.

Anemia 2016, e8057650. doi:10.1155/2016/8057650

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: - / Journal: Anemia
TAR
2016
Patient-reported outcomes in elderly bevazizumab-treated primary ovarian cancer patients: OTILIA study on behalf of the north-eastern german society of gynaecological oncology.

Sehouli, J., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Mustea, A., 2016.

IGCS-0471

Indikation: Other, Sonstige / Veranstaltung: IGCS / Journal: -
OTILIA
2016
REASON: Klinisch-pathologische Faktoren relevant für die klinische Wirksamkeit von Gefitinib bei Patienten mit NSCLC Stadium IIIb/IV und mutiertem EGF Rezeptor (EGFR-M+).

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin P430.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGP / Journal: -
REASON
2016
Zielgerichtete Therapie des NSCLC mit Gefitinib in Abhängigkeit von der Art der EGFR-Mutation: Auswertung der klinischen Wirksamkeit in REASON Exon-Subgruppen.

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin P429.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGP / Journal: -
REASON
2016
REASON: Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M+) treated with gefitinib.

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Oncol Res Treat, 39 (suppl 1) (ID 0345), 120. doi:10.1159/000444354

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
REASON
2016
Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon.

Schuette, W., Dietel, M., Thomas, M., Eberhardt, W., Zirrgiebel, U., Radke, S., Schirmacher, P., 2016.

Oncol Res Treat, 39 (suppl 1), (ID 0341) 120. doi:10.1159/000444354

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
REASON
2016
Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial.

Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach, T., Marschner, N., Schmoll, H.-J., Hinke, A., Al-Batran, S.-E., Arnold, D., 2016.

Ann Oncol 27(6), 149–206, 557P. doi:10.1093/annonc/mdw370.105

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
AIO KRK 0207
2016
Quality of Life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: A preplanned analysis of the phase III AIO KRK 0207 trial.

Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach, T., Marschner, N., Schmoll, H.-J., Hinke, A., Al-Batran, S.-E., Arnold, D., 2016.

Ann Oncol 27, 2203–2210. doi:10.1093/annonc/mdw425

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Annals of Oncology
AIO KRK 0207
2016
Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, Grebhardt, S., Marschner, N., 2016.

Ann Oncol (2016) 27 (suppl_6): 236P. doi:10.1093/annonc/mdw365.15

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
NABUCCO
2016
Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses from the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology (NOGGO) Ovarian Cancer Working Group.

Mustea, A., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Reichert, D., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Sehouli, J., 2016.

Ann Oncol 27(suppl_6), 296–312, 867P. doi:10.1093/annonc/mdw374.14

Abstract

Indikation: Other, Sonstige / Veranstaltung: ESMO / Journal: Annals of Oncology
OTILIA
2016